Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP432041.RADoZKaYkHfkw_pI6EMW-V3S78fE71J_MmM-tVjd145io130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP432041.RADoZKaYkHfkw_pI6EMW-V3S78fE71J_MmM-tVjd145io130_assertion type Assertion NP432041.RADoZKaYkHfkw_pI6EMW-V3S78fE71J_MmM-tVjd145io130_head.
- NP432041.RADoZKaYkHfkw_pI6EMW-V3S78fE71J_MmM-tVjd145io130_assertion description "[RUNX3 methylation was also detected in hepatocellular carcinomas (73%, n=48), larynx cancers (62%, n=37), lung cancers (46%, n=24), breast cancers (25%, n=25), prostate cancers (23%, n=44), endometrial cancers (12.5%, n=24), colon cancers (4.9%, n=61) and uterine cervical cancers (2.5%, n=40), showing that RUNX3 methylation is not restricted to gastric cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP432041.RADoZKaYkHfkw_pI6EMW-V3S78fE71J_MmM-tVjd145io130_provenance.
- NP432041.RADoZKaYkHfkw_pI6EMW-V3S78fE71J_MmM-tVjd145io130_assertion evidence source_evidence_literature NP432041.RADoZKaYkHfkw_pI6EMW-V3S78fE71J_MmM-tVjd145io130_provenance.
- NP432041.RADoZKaYkHfkw_pI6EMW-V3S78fE71J_MmM-tVjd145io130_assertion SIO_000772 14968123 NP432041.RADoZKaYkHfkw_pI6EMW-V3S78fE71J_MmM-tVjd145io130_provenance.
- NP432041.RADoZKaYkHfkw_pI6EMW-V3S78fE71J_MmM-tVjd145io130_assertion wasDerivedFrom befree-2016 NP432041.RADoZKaYkHfkw_pI6EMW-V3S78fE71J_MmM-tVjd145io130_provenance.
- NP432041.RADoZKaYkHfkw_pI6EMW-V3S78fE71J_MmM-tVjd145io130_assertion wasGeneratedBy ECO_0000203 NP432041.RADoZKaYkHfkw_pI6EMW-V3S78fE71J_MmM-tVjd145io130_provenance.